Andrea Horvat-Brocker

Wuppertal, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Journal: Lancet (London, England)

Published: April 23, 2026

Viral respiratory tract infections in heart failure: the FINEARTS-HF trial.

Viral respiratory tract infections in heart failure: the FINEARTS-HF trial.

Journal: European heart journal

Published: February 12, 2026

Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal: JACC. Heart failure

Published: July 30, 2025

Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.

Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 01, 2025

Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.

Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 01, 2025

Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.

Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.

Journal: Clinical kidney journal

Published: April 08, 2025

Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal: JAMA cardiology

Published: November 17, 2024

Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme.

Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme.

Journal: European heart journal

Published: September 20, 2024

Corrigendum to "Receptor protein tyrosine phosphatases are expressed by cycling retinal progenitor cells and involved in neuronal development of mouse retina" [Neuroscience 152(3) (2008) 618-645].

Corrigendum to "Receptor protein tyrosine phosphatases are expressed by cycling retinal progenitor cells and involved in neuronal development of mouse retina" [Neuroscience 152(3) (2008) 618-645].

Journal: Neuroscience

Published: September 19, 2024

First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.

First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.

Journal: Journal of nephrology

Published: April 12, 2024

Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.

Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.

Journal: Journal of nephrology

Published: January 17, 2022

Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries.

Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries.

Journal: Expert opinion on drug safety

Published: November 22, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026